Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Rang in Aktien #41418
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2025-06-11
Marktkapitalisierung
$21.52K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Diagnocure, Inc. (DGCRF)

Kategorie

EPS für Diagnocure, Inc. (DGCRF)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Diagnocure, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Diagnocure, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber